The Regenerative Medicine Market was estimated at USD 30.01 billion in 2023 and is poised to reach 105.62 billion in 2031 anticipated to expand at a compound annual growth rate approx. CAGR of 17.03% for the forecast period of 2024-2031.
The preference for personalised therapeutic approaches over conventional treatment modalities has changed as a result of several developments in biological therapeutics. For those in the market who are working on the creation of biological treatments, this has opened up a lot of prospects. The COVID-19 epidemic has had a significant influence on a number of businesses, notably the industry that produces T-cell therapies and regenerative medicine. The delivery of CAR T-cell therapy has been greatly impacted by the SARS-CoV-2 coronavirus outbreak. This effect has spread beyond patient care to include administration, logistics, and the scarcity of healthcare resources. Clinical trial enrolment and other research activity have slowed down at some institutions. However, as market participants like Novartis continue to open up access to treatments like MultiStem, a very important COVID-19 medication from Athersys, Inc., the market continues to grow. Additionally, it has been shown that regenerative medications have the unique capacity to change the underlying pathophysiological processes of illnesses. Trial-stage regenerative medicines provide potential treatments for certain chronic diseases with unmet medical needs. Novartis announced the release of T-ChargeTM in December 2021, a next-generation CAR-T platform that would be used for cutting-edge experimental CAR-T cell treatments. The development of gene-based treatment, which employs targeted delivery of DNA as a drug to combat numerous illnesses, is the consequence of significant developments in molecular therapeutics. Through the restoration of gene function, gene therapy holds great promise for the treatment of cancer and type 1 and type 2 diabetes. Gene-based treatments are now utilised to treat patients with cancer, oncology, infectious illnesses, cardiovascular problems, monogenic diseases, and genetic disorders, problems, ophthalmological signs, and central nervous system illnesses. These elements have helped the market for regenerative medicine expand.
Get More Information on Regenerative Medicine Market - Request Sample Report
DRIVERS
Rising incidence of chronic illnesses & Technological progress
Ageing population growth & Favourable regulatory landscape
The need for regenerative medicine treatments is being driven by the increase in chronic illnesses including diabetes, orthopaedic problems, and cardiovascular diseases. Innovative regenerative medicines have been made possible by developments in stem cell research, tissue engineering, gene therapy, and biomaterials. Age-related tissue deterioration and chronic illnesses are more common in the ageing population, expanding the market for regenerative medicine treatments. The research and marketing of regenerative medicine products are supported by regulatory agencies in several nations, which is promoting market expansion.
RESTRAIN
Costly development & Intricate manufacturing procedures
Ethics-related matters
Regenerative medicine therapies can be expensive to create, test, and use in clinical settings, which restricts their accessibility and uptake.
Due to the intricacy of cell culture, maintaining quality control, and assuring product consistency, making regenerative medicine products can be difficult. As a result of ethical questions raised by the use of embryonic stem cells and specific genetic engineering methods, the advancement and acceptability of some regenerative medicine techniques may be constrained.
OPPORTUNITY
Individualised medicine & Partnerships and cooperation
Medical travel
In order to improve treatment effectiveness and patient outcomes, regenerative medicine provides the opportunity for personalised medicines designed for specific individuals. Collaboration between academic institutions, biotechnology firms, and healthcare organisations may promote creativity, speed up product development, and broaden a product's commercial appeal. Regenerative medicine treatments have the potential to draw patients from all over the world, fostering the expansion of medical tourism and opening up new business prospects.
CHALLENGES
Regulatory challenges & Data on long-term effectiveness and safety
Payment problems
In order to improve treatment effectiveness and patient outcomes, regenerative medicine provides the opportunity for personalised medicines designed for specific individuals. Collaboration between academic institutions, biotechnology firms, and healthcare organisations may promote creativity, speed up product development, and broaden a product's commercial appeal. Regenerative medicine treatments have the potential to draw patients from all over the world, fostering the expansion of medical tourism and opening up new business prospects.
Skilled researchers and medical personnel may leave the afflicted regions as a result of the conflict and its effects. This exodus of talent might lead to a loss of knowledge and impede the sector's expansion and advancement. International relationships and collaborations in regenerative medicine might be hampered by the ongoing war and geopolitical concerns. Travel restrictions, broken supply chains, and safety worries can make it difficult to share expertise, collaborate on research projects, and transfer technology.
The battle may take money away from regenerative medicine research and development projects. Reduced financing prospects as a result of shifting priorities and economic instability may have an effect on the development and feasibility of regenerative medicine programmes in the impacted areas.
IMPACT OF ONGOING RECESSION
Reduced investment and financing Funding for research and development, including regenerative medicine, frequently declines during a recession. Reduced financial support for regenerative medicine initiatives and businesses may result from limited government budgets, private contributions, and venture capital funding. Clinical studies that are postponed or scaled back are an essential stage in the development and marketing of regenerative medicine treatments. However, due to budgetary restrictions, resource shortages, and a decline in patient enrollment during a recession, businesses and academic institutions may experience difficulties running clinical studies.
By Product
By Therapeutic
Dermatology
Musculoskeletal
Immunology & Inflammation
Oncology
Cardiovascular
Ophthalmology
Others
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin American
North America
With a market share of 51.32% in 2022, the North American region dominated the global market for regenerative medicine. The significant market growth is attributable to the availability of public and private development financing, the existence of cutting-edge technological frameworks to assist the quick identification of chronic illnesses, and the high healthcare spending in the area. In addition, the area has grown as a result of several ongoing clinical studies for regenerative medicine by important industry players. For the prevention of acute graft versus host disease in adults and paediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT), Bristol Myers Squibb acquired U.S. FDA clearance in December 2021 for Orencia.
Asia Pacific
In the upcoming years, Asia Pacific is expected to see the fastest growth rate. The increasing acceptance of cell-based methods in healthcare, the increase in the number of elderly people in the area, and the development of important companies are all cited as reasons for this expansion. China has recently emerged with fast infrastructure and facility growth to further stem cell research. Regenerative medicine is thus projected to flourish in the area as a result.
The major Key players are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Integra Lifesciences Corp, Astellas Pharma, Inc., Cook Biotech, Inc, Bayer AG, Pfizer, Inc., Merck KGaA, Abbott, Vericel Corp, Novartis AG and others.
Novartis:
Novartis and Alnylam will collaborate to investigate targeted therapies to restore liver function in 2022.
AbbVie:
Acquired Allergan in 2022 to expand its offering of immunology, hematologic oncology, neuroscience, and Allergan aesthetics products.
| Report Attributes | Details |
| Market Size in 2023 | US$ 30.01 Bn |
| Market Size by 2031 | US$ 105.62 Bn |
| CAGR | CAGR of 17.03% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Therapeutics, Banks, Services) • By Therapeutic (Dermatology, Musculoskeletal, Immunology & Inflammation, Oncology, Cardiovascular, Ophthalmology, Others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | AstraZeneca plc, F. Hoffmann-La Roche Ltd., Integra Lifesciences Corp, Astellas Pharma, Inc., Cook Biotech, Inc, Bayer AG, Pfizer, Inc., Merck KGaA, Abbott, Vericel Corp, Novartis AG and others. |
| Key Drivers | • Rising incidence of chronic illnesses & Technological progress • Ageing population growth & Favorable regulatory landscape |
| Market Opportunities | • Individualized medicine & Partnerships and cooperation • Medical travel |
Ans: The size of Regenerative medicine market is USD 55.04 billion in 2022 and is poised to reach at 177.9 billion in 2030.
Ans: The CAGR Growth rate of Regenerative medicine market is approx. at a CAGR of 15.8% from 2023 to 2030.
Ans: The major Key players are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Integra Lifesciences Corp, Astellas Pharma, Inc., Cook Biotech, Inc, Bayer AG, Pfizer, Inc., Merck KGaA, Abbott, Vericel Corp, Novartis AG and others.
Ans: A powerful pipeline portfolio, a large number of clinical trials, the significant economic impact of regenerative medicine, and technical advancements in regenerative medicine are important market growth drivers.
Ans: In 2022, North America held a 51.23% market share for regenerative medicine. This is due to the region's accessibility to cutting-edge technology and the existence of research institutions engaged in the creation of innovative therapies.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Global Regenerative medicine market By Product
8.1Therapeutics
8.2Banks
8.3Services
9. Global Regenerative medicine market By Therapeutic
9.1Dermatology
9.2Musculoskeletal
9.3Immunology & Inflammation
9.4Oncology
9.5Cardiovascular
9.6Ophthalmology
9.7Others
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Regenerative Medicine Market by country
10.2.2North America Regenerative Medicine Market by Product
10.2.3 North America Regenerative Medicine Market by Therapeutic
10.2.4 USA
10.2.4.1 USA Regenerative Medicine Market by Product
10.2.4.2 USA Regenerative Medicine Market by Therapeutic
10.2.7 Canada
10.2.7.1 Canada Regenerative Medicine Market by Product
10.2.7.2 Canada Regenerative Medicine Market by Therapeutic
10.2.8 Mexico
10.2.8.1 Mexico Regenerative Medicine Market by Product
10.2.8.2 Mexico Regenerative Medicine Market by Therapeutic
10.3 Europe
10.3.1 Europe Regenerative Medicine Market by country
1.3.3.2 Europe Regenerative Medicine Market by Product
10.3.3 Europe Regenerative Medicine Market by Therapeutic
10.3.6 Germany
10.3.6.1 Germany Regenerative Medicine Market by Product
10.3.6.2 Germany Regenerative Medicine Market by Therapeutic
10.3.7 UK
10.3.7.1 UK Regenerative Medicine Market by Product
10.3.7.2 UK Regenerative Medicine Market by Therapeutic
10.3.8 France
10.3.8.1 France Regenerative Medicine Market by Product
10.3.8.2 France Regenerative Medicine Market by Therapeutic
10.3.9 Italy
10.3.9.1 Italy Regenerative Medicine Market by Product
10.3.9.2 Italy Regenerative Medicine Market by Therapeutic
10.3.10 Spain
10.3.10.1 Spain Regenerative Medicine Market by Product
10.3.10.2 Spain Regenerative Medicine Market by Therapeutic
10.3.11 The Netherlands
10.3.11.1 Netherlands Regenerative Medicine Market by Product
10.3.11.2 Netherlands Regenerative Medicine Market by Therapeutic
10.3.12 Rest of Europe
10.3.12.1 Rest of Europe Regenerative Medicine Market by Product
10.3.12.2 Rest of Europe Regenerative Medicine Market by Therapeutic
10.4 Asia-Pacific
10.4.1 Asia Pacific Regenerative Medicine Market by country
10.4.2 Asia Pacific Regenerative Medicine Market by Product
10.4.3 Asia Pacific Regenerative Medicine Market by Therapeutic
10.4.6 Japan
10.4.6.1 Japan Regenerative Medicine Market by Product
10.4.6.2 Japan Regenerative Medicine Market by Therapeutic
10.4.7 South Korea
10.4.7.1 South Korea Regenerative Medicine Market by Product
10.4.7.2 South Korea Regenerative Medicine Market by Therapeutic
10.4.8 China
10.4.8.1 China Regenerative Medicine Market by Product
10.4.8.2 China Regenerative Medicine Market by Therapeutic
10.4.9 India
10.4.9.1 India Regenerative Medicine Market by Product
10.4.9.2 India Regenerative Medicine Market by Therapeutic
10.4.10 Australia
10.4.10.1 Australia Regenerative Medicine Market by Product
10.4.10.2 Australia Regenerative Medicine Market by Therapeutic
10.4.11 Rest of Asia-Pacific
10.4.11.1 APAC Regenerative Medicine Market by Product
10.4.11.2 APAC Regenerative Medicine Market by Therapeutic
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Regenerative Medicine Market by country
10.5.2 The Middle East & Africa Regenerative Medicine Market by Product
10.5.3 The Middle East & Africa Regenerative Medicine Market by Therapeutic
10.5.6 Israel
10.5.6.1 Israel Regenerative Medicine Market by Product
10.5.6.2 Israel Regenerative Medicine Market by Therapeutic
10.5.7 UAE
10.5.7.1 UAE Regenerative Medicine Market by Product
10.5.7.2 UAE Regenerative Medicine Market by Therapeutic
10.5.8 South Africa
10.5.8.1 South Africa Regenerative Medicine Market by Product
10.5.8.2 South Africa Regenerative Medicine Market by Therapeutic
10.5.9 Rest of Middle East & Africa
10.5.9.1 Rest of Middle East & Asia Regenerative Medicine Market by Product
10.5.9.2 Rest of Middle East & Asia Regenerative Medicine Market by Therapeutic
10.6 Latin America
10.6.1 Latin America Regenerative Medicine Market by country
10.6.2 Latin America Regenerative Medicine Market by Product
10.6.3 Latin America Regenerative Medicine Market by Therapeutic
10.6.6 Brazil
10.6.6.1 Brazil Regenerative Medicine Market by Product
10.6.6.2 Brazil Africa Regenerative Medicine Market by Therapeutic
10.6.7 Argentina
10.6.7.1 Argentina Regenerative Medicine Market by Product
10.6.7.2 Argentina Regenerative Medicine Market by Therapeutic
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Regenerative Medicine Market by Product
10.6.8.2 Rest of Latin America Regenerative Medicine Market by Therapeutic
11 Company profile
11.1 AstraZeneca plc.
11.1.1 Market Overview
11.1.2 Financials
11.1.3 Products/Services/Offerings
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 Market Overview
11.2.2 Financials
11.2.3 Products/Services/Offerings
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 Integra Lifesciences Corp.
11.3.1 Market Overview
11.3.2 Financials
11.3.3 Products/Services/Offerings
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Astellas Pharma, Inc.
11.4.1 Market Overview
11.4.2 Financials
11.4.3 Products/Services/Offerings
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Cook Biotech, Inc,
11.5.1 Market Overview
11.5.2 Financials
11.5.3 Products/Services/Offerings
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Bayer AG,
11.6.1 Market Overview
11.6.2 Financials
11.6.3 Products/Services/Offerings
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Pfizer, Inc.
11.7.1 Market Overview
11.7.2 Financials
11.7.3 Products/Services/Offerings
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 Merck KGaA.
11.8.1 Market Overview
11.8.2 Financials
11.8.3 Products/Services/Offerings
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Abbott
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Products/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Vericel Corp.
11.10.1 Market Overview
11.10.2 Financials
11.10.3 Products/Services/Offerings
11.10.4 SWOT Analysis
11.10.5 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share analysis
12.3 Recent Developments
13. Use Case and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Foot Orthotic Insoles Market size was valued at USD 3.42 Billion in 2022 and is expected to reach USD 5.87 Billion By 2030 and grow at a CAGR of 7% over the forecast period of 2023-2030.
The Protein A Resin Market, size was estimated USD 1.4 billion in 2022 and is expected to reach USD 2.97 billion by 2030 at a CAGR of 9.9% during the forecast period of 2023-2030.
The Biomaterials Market size was estimated USD 156.1 billion in 2022 and is expected to reach USD 501.2 billion by 2030 at a CAGR of 15.7% during the forecast period of 2023-2030.
The Research Antibodies Market size was estimated USD 1.7 billion in 2022 and is expected to reach USD 2.4 billion by 2030 at a CAGR of 4.9% during the forecast period of 2023-2030.
The Oxytocic Pharmaceuticals Market Size was valued at USD 110.26 billion in 2022 and is expected to reach USD 204.09 billion by 2030, and grow at a CAGR of 8% over the forecast period 2023-2030.
Peptic Ulcer Drugs Market size was USD 4.48 Billion in 2023 and is expected to reach USD 5.59 Billion by 2031 and grow at a CAGR of 2.80% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
